Navigation Links
For Bipolar Depression, Surveyed Experts Indicate That Current and Emerging Therapies Have No Advantage Over Seroquel in Decreasing the Severity of Symptoms
Date:4/27/2009

Lamictal Will Retain Decision Resources' Clinical Gold Standard Status for Bipolar Depression, According to a New Report from Decision Resources

WALTHAM, Mass., April 27 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed psychiatrists identify a therapy's effect on decrease in severity of depressive symptoms as the attribute that most influences their prescribing decisions in bipolar depression. Clinical data and the opinions of interviewed thought leaders indicate that current and emerging therapies have no advantage in this attribute over AstraZeneca's Seroquel, the sales-leading agent in the market.

The new report entitled Bipolar Depression: Despite Negative Results, Physicians Still Hopeful About Aripiprazole also finds that an oral therapy that carries a lower risk of weight gain than Seroquel would earn a 21 percent patient share in bipolar depression in the United States and a 30 percent patient share in Europe, according to surveyed U.S. and European psychiatrists. The report also finds that, despite the failure of Bristol-Myers Squibb/Otsuka Pharmaceutical's Abilify (aripiprazole) in bipolar depression clinical trials, most interviewed thought leaders believe that Abilify is still an efficacious therapy for bipolar depression.

In 2008, Decision Resources' proprietary clinical gold standard for bipolar depression was lamotrigine (GlaxoSmithKline's Lamictal, generics). Based on available data and expert opinion, lamotrigine will retain gold standard status through 2017. While some therapies in development for bipolar depression hold promise, most have efficacy, safety and tolerability, and/or delivery features that are inferior when compared with lamotrigine.

"Owing to its efficacy and tolerability advantages, lamotrigine edged out Seroquel, its closest competitor, to become the clinical gold standard," said Decision Resources Analyst Sandra Chow, M.Sc. "Despite its slow onset of action, interviewed thought leaders were particularly impressed with lamotrigine's side-effect profile and better evidence of efficacy as a long term mood stabilizer."

About the Report

Bipolar Depression: Despite Negative Results, Physicians Still Hopeful About Aripiprazole is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                        Decision Resources, Inc.
    Christopher Comfort                       Elizabeth Marshall
    781-296-2597                              781-296-2563
    ccomfort@dresources.com                   emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New National Online Survey Says Bipolar Depressive Symptoms Have Impact on Day-To-Day Tasks as Well as Social Activities(1)
2. Repligen Licenses Patent Rights for Treatment of Bipolar Disorder
3. National Audience of Psychiatrists Assembling in Chicago for Conference on Bipolar Disorder and ADHD
4. HealthyPlace.com, the Largest Consumer Mental Health Site, Launches Mediminder, a Free Medication Reminder Tool for the More Than 30 Million People Who Suffer From Depression, Anxiety, Bipolar Disorder and Other Mental Health Conditions
5. Kids Risks Increase When Parents Are Bipolar
6. HealthyPlace.com, the Largest Consumer Mental Health Site, Re-Launches With Important New Features for the More Than 30 Million People Who Suffer from Anxiety, Depression and Bipolar Disorder
7. AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar Depression
8. Common Genes Link Bipolar Disorder, Schizophrenia
9. WellPoint Announces Innovative Program to Help Improve the Care of Members Suffering With Bipolar Disorder
10. Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder
11. Children of Older Fathers at Risk for Bipolar Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 27, 2016 , ... Quality metrics are proliferating in cancer care, and are ... the eye of the beholder, according to experts who offered insights and commentary in ... Managed Care. For the full issue, click here . , For the American ...
(Date:6/26/2016)... ... , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... a whole new perspective by using the title layers in ProSlice Levels to ... ProSlice Levels contains over 30 Different presets to choose from. FCPX users ...
(Date:6/26/2016)... NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and ... to be personalized through a fitness app. The fitness app plans to fix the two ... currently only offer a one size fits all type program , They don’t ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
Breaking Medicine Technology: